Peptide stacks for Long Covid: What the evidence actually says

What's this video probably claiming?

Based on the caption, @duchessofdecorum is sharing a personal Long Covid recovery protocol that includes Thymosin Alpha-1 (TA-1) at 0.15mg, Thymosin Beta-4 (TB-4) at 0.15mg, BPC-157, and NAD+ supplementation. The framing is experiential: she feels like herself again, and the implication is that this peptide combination drove that recovery. The mention of a specific clinic, The Novus Center, adds a layer of implied medical legitimacy. The disclaimer that it's "not medical advice" is standard boilerplate, but the effect on 3,400 viewers is almost certainly aspirational. People with Long Covid are desperate, exhausted, and actively searching for anything that works. A testimonial from someone who claims to have turned a corner is exactly the kind of content that spreads fast in that community, with or without evidence behind it.

What does the science actually show?

Let's go compound by compound. Thymosin Alpha-1 has the strongest evidence base here. It's an immunomodulatory peptide with a legitimate track record in hepatitis B and some cancer applications, and a 2021 study by Shi et al. in the Journal of Infection found TA-1 improved immune markers in severe COVID-19 patients, though not specifically Long Covid. Thymosin Beta-4 is mostly preclinical, with tissue repair data from animal models that haven't translated cleanly to human trials. BPC-157 has zero approved human trials completed for any indication as of 2024. NAD+ precursors like NMN and NR have modest human data for fatigue and cellular energy, including a 2023 trial by Brakedal et al. in Nature Communications showing NMN improved NAD+ levels but with unclear clinical significance. None of these have been studied together in Long Covid patients. The stack itself is entirely without clinical evidence.

Where does the social media noise diverge from clinical reality?

The biggest problem with this content isn't any single claim. It's the implication that a four-compound peptide protocol is an appropriate response to a complex post-infectious syndrome that researchers still don't fully understand mechanistically. Long Covid likely involves multiple overlapping pathologies: viral persistence, microclotting, mitochondrial dysfunction, dysautonomia, and immune dysregulation. A 2023 review by Davis et al. in Nature Reviews Microbiology outlined at least four distinct biological mechanisms, none of which map neatly onto "take these peptides and feel better." The creator's improvement is real to her. But attributing recovery to a specific stack ignores natural disease trajectory, placebo effect, regression to the mean, and every other lifestyle variable she may have changed. TikTok's Long Covid community is also almost entirely composed of people who tried conventional medicine and felt dismissed, making them especially vulnerable to confident alternative narratives.

What should you actually know?

Compounded peptides sold through telehealth clinics are not FDA-approved drugs. BPC-157 in particular was placed on the FDA's list of drugs that cannot be compounded under Section 503A and 503B in 2022, which means its legal status as a compounded product is actively contested. TA-1 exists as an approved drug outside the US (Zadaxin), but compounded versions in the US are a different product with different quality controls. NAD+ infusions and oral precursors have a cleaner regulatory standing but wildly inconsistent quality across suppliers. If you have Long Covid, the actual evidence-based first steps are working with a Long Covid clinic, getting a cardiovascular workup to rule out POTS, and considering low-dose naltrexone, which has a small but growing evidence base in post-viral syndromes per a 2024 paper by Patterson et al. in the International Journal of Infectious Diseases. Peptide protocols aren't automatically dangerous, but they're not a substitute for diagnosis.